NCT04513054 Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy
| NCT ID | NCT04513054 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Aberdeen |
| Condition | Takotsubo Cardiomyopathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 700 participants |
| Start Date | 2019-03-12 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 700 participants in total. It began in 2019-03-12 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute stress-induced (takotsubo) cardiomyopathy or broken heart syndrome presents like a heart attack, classically is triggered by intense emotional or physical stress and can have serious health consequences. In the current study the investigators wish to establish whether there is a genetic predisposition making certain people more susceptible to this condition. This could also have implications for their families.
Eligibility Criteria
Inclusion Criteria: * All patients who have been diagnosed with Takotsubo cardiomyopathy in Scotland between 2010 to date. * Familial cases elsewhere in the world who would be willing to participate. Exclusion Criteria: * Unwillingness to participate
Contact & Investigator
Dana K Dawson, MD, MPhil
PRINCIPAL INVESTIGATOR
University of Aberdeen
Frequently Asked Questions
Who can join the NCT04513054 clinical trial?
This trial is open to participants of all sexes, studying Takotsubo Cardiomyopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04513054 currently recruiting?
Yes, NCT04513054 is actively recruiting participants. Contact the research team at a.e.rudd@abdn.ac.uk for enrollment information.
Where is the NCT04513054 trial being conducted?
This trial is being conducted at Aberdeen, United Kingdom, Aberdeen, United Kingdom.
Who is sponsoring the NCT04513054 clinical trial?
NCT04513054 is sponsored by University of Aberdeen. The principal investigator is Dana K Dawson, MD, MPhil at University of Aberdeen. The trial plans to enroll 700 participants.